The relationship between different doses of dexamethasone administration (4, 5 and 6 mg) on neonatal cord blood cortisol levels to the incidence of respiratory distress syndrome in preterm neonates

Start Date01 Mar 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

TCTR20241104004

/ Not yet recruitingNot ApplicableIIT

Prevalence of HPV DNA detection among pregnant women: Promoting of self- Sampling HPV DNA testing for cervical cancer screening in pregnant women

Start Date01 Jan 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

TCTR20241104002

/ Not yet recruitingPhase 2IIT

Effects of Dexamethasone 4, 5, and 6 mg on Neuromental development in 2-Year-Old Children: Phase II Follow-up of a Double-blind, Non-inferiority, Randomized Controlled Trial in Preterm Infants (290-366 Weeks)

Start Date01 Jan 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

100 Clinical Results associated with Faculty of Medicine Siriraj Hospital

0 Patents (Medical) associated with Faculty of Medicine Siriraj Hospital

203

Literatures (Medical) associated with Faculty of Medicine Siriraj Hospital

08 Apr 2025·Neurology

Effectiveness and Outcome Predictors of Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (S38.004)

Author: Arnold, Anthony C. ; Pittock, Sean ; Choi, David ; Chen, John ; Flanagan, Eoin ; Vasileiou, Elena ; Huda, Saif ; Bonelli, Laura ; Shah, Shailee ; Maillart, Elisabeth ; Audoin, Bertrand ; Forcadela, Mirasol ; Cacciaguerra, Laura ; Chen, Bo ; Palace, Jacqueline ; Hewitt, Sage ; Lopez, Alfonso ; Champsas, Dimitrios ; Navarro, Sylvia Elizabeth Villarreal ; Thakolwiboon, Smathorn ; Tajfirouz, Deena ; Deschamps, Romain ; Wilf-Yarkoni, Adi ; Jitprapaikulsan, Jiraporn ; Moss, Heather ; de la Motte, Marine Boudot ; Levy, Michael ; Redenbaugh, Vyanka ; Danesh-Meyer, Helen ; Vorasoot, Nisa ; Sotirchos, Elias ; Tisavipat, Nanthaya ; Poullin, Pascale ; Boutère, Clémence ; Mao-Draayer, Yang ; Marignier, Romain ; Henderson, Amanda ; Davis, James ; Pique, Julie ; Mishra, Murli ; Tillema, Jan-Mendelt ; Hacohen, Yael ; Stiebel-Kalish, Hadas ; Lotan, Itay

01 Apr 2025·European Journal of Pharmaceutical Sciences

Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor romidepsin using Poly-(D, L-lactide-co-glycolide) nanoparticles as a drug carrier

Article

Author: Srisawat, Chatchawan ; Punnakitikashem, Primana ; Suwanwong, Yaneenart ; Aroonthongsawat, Pinyadapat ; Manocheewa, Siriphan

The goal of this work is to develop a delivery system for histone deacetylase inhibitor (HDACi) romidepsin (ROM) using Poly(D, L-lactide-co-glycolide) as a carrier and evaluate its anti-leukemic effects. Romidepsin-loaded nanoparticles (ROM NPs) required for this purpose were fabricated using a single emulsion-solvent evaporation technique. Their physical characteristics and in vitro drug release profiles were studied, alongside biocompatibility and hemocompatibility assessments. Cell viability assays and Annexin V/Propidium Iodide (PI) staining were conducted to evaluate the anti-leukemic and apoptosis induction efficiency of ROM NPs in vitro. ROM NPs displayed a spherical shape with an average hydrodynamic size of about 149.7 ± 8.4 nm, a PDI of 0.11 ± 0.03, and a zeta potential of -25.27 ± 2.12 mV. The nanoparticles demonstrated a high encapsulation efficiency of ROM (∼93 %) and these nanoparticles effectively entered acute leukemia cells, including U937 and Jurkat. ROM NPs also exhibited a prolonged biphasic release pattern, specifically, the initial burst release phase occurred within the first 24 h, followed by a slower, sustained release. Additionally, they showed no hematological or biological toxicity, indicating their potential use for the delivery of anti-cancer drugs through the circulatory system. In tests on acute leukemia cell lines, ROM NPs showed significantly stronger anti-leukemic effects and induced apoptosis to a greater extent compared to free ROM. In summary, ROM NPs represent a promising therapy option for leukemia according to their enhanced anti-leukemic effects. Further modification of this strategy could be performed to enable target specificity, hence minimizing damage to normal cells.

26 Mar 2025·Journal of the American Chemical Society

Recombinase-Controlled Multiphase Condensates Accelerate Nucleic Acid Amplification and CRISPR-Based Diagnostics

Article

Author: Uttamapinant, Chayasith ; Sudyoadsuk, Taweesak ; Muengsaen, Duangkamon ; Reinhardt, Aleks ; Chantanakool, Pheerawat ; Homchan, Aimorn ; Taiwan, Siraphob ; Patchsung, Maturada ; Thaweeskulchai, Thana ; Aphicho, Kanokpol ; Panchai, Chuthamat ; Tandean, Martin ; Wongsatit, Thanakrit ; Horthongkham, Navin ; Onchan, Warunya ; Sakpetch, Theeradon ; Suraritdechachai, Surased

Isothermal techniques for amplifying nucleic acids have found extensive applications in genotyping and diagnostic tests. These methods can be integrated with sequence-specific detection strategies, such as CRISPR-based detection, for optimal diagnostic accuracy. In particular, recombinase-based amplification uses proteins from the Escherichia virus T4 recombination system and operates effectively at moderate temperatures in field and point-of-care settings. Here, we discover that recombinase polymerase amplification (RPA) is controlled by liquid-liquid phase separation, where the condensate formation enhances the nucleic acid amplification process. While two protein components of RPA could act as scaffold proteins for condensate formation, we identify T4 UvsX recombinase as the key regulator orchestrating distinct core-shell arrangements of proteins within multiphase condensates, with the intrinsically disordered C-terminus of UvsX being crucial for phase separation. We develop volumetric imaging assays to visualize RPA condensates and the reaction progression in whole volumes, and begin to dissect how macroscopic properties such as size distribution and droplet count could contribute to the overall reaction efficiency. Spatial organization of proteins in condensates may create optimal conditions for amplification, and disruption of such structures may diminish the amplification efficiency, as we demonstrate for the case of reverse transcription-RPA. The insight that RPA functions as a multiphase condensate leads us to identify the UvsX^D274A mutant, which has a distinct phase-separation propensity compared to the wild-type enzyme and can enhance RNA detection via RPA-coupled CRISPR-based diagnostics.

News (Medical) associated with Faculty of Medicine Siriraj Hospital

07 Dec 2020

·www.healthcareitnews.com

Huawei & Siriraj Hospital sign MoU to establish 5G powered smart platform for medical services

Huawei Technologies (Thailand) Co. Ltd. and the Faculty of Medicine, Siriraj Hospital, under Mahidol University, has signed the 5G Powered Smart Hospital Enabled with Cloud and AI Memorandum of Understanding (MoU) to establish a smart platform that will enhance innovative medical services. This MoU comes in response to the Faculty of Medicine Siriraj Hospital's mission to serve better by becoming a smart center that will apply integrated digital technologies using 5G infrastructure, artificial intelligence (AI), big data and cloud edge computing, in order to offer enhanced services. WHAT’S IT ABOUT Under the five-year agreement, Huawei will provide 5G technology to the Faculty, enabling the immediate upgrade of the existing infrastructure. It will also share knowledge and collaborate with Siriraj researchers and academic staff to enable Siriraj to operate more efficiently. Both parties will work together in other jointly-developed projects that may arise in the course of the MoU. Siriraj will participate with Huawei for further 5G ecosystem partnership cooperation to promote 5G technology and innovations, in the form of demonstration events and exhibitions. The hospital will also work with Huawei for joint academic sessions, to arrange training classes or technology sharing opportunities, and to study the latest technology topics including, but not limited to, 5G, AI and Cloud. THE LARGER TREND Siriraj Hospital, which is Thailand’s largest government hospital, is the first hospital in Southeast Asia to deploy two NVIDIA DGX A100 systems for medical research and clinical applications, Healthcare IT News reported. In South Korea, KT, the country’s largest telecommunications company and Samsung Medical Center are jointly developing a 5G-powered medical service as an initial step to establishing a 5G smart hospital. The two partners have been applying 5G on site to create better medical services since they signed a MoU in September 2019. ON THE RECORD “It is an honor for Faculty of Medicine Siriraj Hospital to partner with Huawei for this MoU that will raise the level and standards of our services and improve operational efficiency. This marks the initial step to establishing Thailand's first 5G smart state hospital,” said Prof. Dr. Prasit Watanapa, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University. “The healthcare sector can benefit immensely from smart innovations and infrastructure during this era of digitalization. We would like to accompany Thailand as it develops a strong, connected healthcare ecosystem in order to increase healthcare penetration in rural and remote communities and improve the quality of life of the people,” said Abel Deng, CEO of Huawei Technologies (Thailand).

100 Deals associated with Faculty of Medicine Siriraj Hospital

100 Translational Medicine associated with Faculty of Medicine Siriraj Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CD19 CAR-T (Faculty of Medicine Siriraj Hospital) ( CD19 )	Non-Hodgkin Lymphoma More	Phase 1
VP-001 (PYC Therapeutics) ( CNOT3 x PRPF31 )	Retinitis Pigmentosa 11 More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis